1615
clinical study

Incidental pulmonary embolism in patients with cancer: prevalence, underdiagnosis and evaluation of an AI algorithm for automatic detection of pulmonary embolism

Materials & Methods

A retrospective cohort study assessing the prevalence of reported and unreported incidental pulmonary embolism (iPE) in patients with cancer were identified through automatic detection with an AI algorithm. All patients with cancer with an elective CT (chest and/or abdo) study, including the chest, between July 1, 2018 to June 30, 2019 were included and study reports and images were reviewed and processed by the AI algorithm.  

Results

1,892 CT studies were included. Per study, iPE was present in 4.0% of the oncology population. 80% miss rate (53/65) showed a >400% enhanced detection rate by AI (53/12). Of those 58% (31/53) of the misses where lobar or segmental and 59% (13/22) of the subsegmental findings involved multiple vessels (i.e.: higher clinical significance than a solitary sub-seg finding). The sensitivity 90.7%, specificity 99.8%, PPV 95.6%, NPV 99.6%.

Conclusions

In a retrospective single-center study on patients with cancer, unreported iPE were common, with the majority lying proximal to the subsegmental arteries. The evaluated AI algorithm had very high sensitivity and specificity, so it has the potential to increase the detection rate of iPE.

Explore the Latest AI Insights, Trends and Research

Daniel Spector

<p>Daniel Spector is an AI Transformation Consultant at Aidoc. His focus is enabling clinicians and hospital administrators to provide better, more efficient care through the power of AI augmentation for enterprise imaging.</p>

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>